642 related articles for article (PubMed ID: 27604504)
1. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial.
Mulvenna P; Nankivell M; Barton R; Faivre-Finn C; Wilson P; McColl E; Moore B; Brisbane I; Ardron D; Holt T; Morgan S; Lee C; Waite K; Bayman N; Pugh C; Sydes B; Stephens R; Parmar MK; Langley RE
Lancet; 2016 Oct; 388(10055):2004-2014. PubMed ID: 27604504
[TBL] [Abstract][Full Text] [Related]
2. Interim data from the Medical Research Council QUARTZ Trial: does whole brain radiotherapy affect the survival and quality of life of patients with brain metastases from non-small cell lung cancer?
Langley RE; Stephens RJ; Nankivell M; Pugh C; Moore B; Navani N; Wilson P; Faivre-Finn C; Barton R; Parmar MK; Mulvenna PM;
Clin Oncol (R Coll Radiol); 2013 Mar; 25(3):e23-30. PubMed ID: 23211715
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic radiosurgery plus whole-brain radiotherapy for treatment of multiple metastases from non-small cell lung cancer.
Minniti G; Salvati M; Muni R; Lanzetta G; Osti MF; Clarke E; Costa A; Bozzao A; Trasimeni G; Enrici RM
Anticancer Res; 2010 Jul; 30(7):3055-61. PubMed ID: 20683055
[TBL] [Abstract][Full Text] [Related]
4. Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases.
Tsao MN; Xu W; Wong RK; Lloyd N; Laperriere N; Sahgal A; Rakovitch E; Chow E
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD003869. PubMed ID: 29365347
[TBL] [Abstract][Full Text] [Related]
5. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial.
Brown PD; Ballman KV; Cerhan JH; Anderson SK; Carrero XW; Whitton AC; Greenspoon J; Parney IF; Laack NNI; Ashman JB; Bahary JP; Hadjipanayis CG; Urbanic JJ; Barker FG; Farace E; Khuntia D; Giannini C; Buckner JC; Galanis E; Roberge D
Lancet Oncol; 2017 Aug; 18(8):1049-1060. PubMed ID: 28687377
[TBL] [Abstract][Full Text] [Related]
6. Whole brain radiotherapy for the treatment of newly diagnosed multiple brain metastases.
Tsao MN; Lloyd N; Wong RK; Chow E; Rakovitch E; Laperriere N; Xu W; Sahgal A
Cochrane Database Syst Rev; 2012 Apr; 2012(4):CD003869. PubMed ID: 22513917
[TBL] [Abstract][Full Text] [Related]
7. Surgery versus stereotactic radiotherapy for people with single or solitary brain metastasis.
Fuentes R; Osorio D; Expósito Hernandez J; Simancas-Racines D; Martinez-Zapata MJ; Bonfill Cosp X
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012086. PubMed ID: 30125049
[TBL] [Abstract][Full Text] [Related]
8. Increased survival with the combination of stereotactic radiosurgery and gefitinib for non-small cell lung cancer brain metastasis patients: a nationwide study in Taiwan.
Lin CH; Hsu KH; Chang SN; Tsou HK; Sheehan J; Sheu ML; Pan HC
Radiat Oncol; 2015 Jun; 10():127. PubMed ID: 26048754
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic Radiosurgery With or Without Whole-Brain Radiotherapy for Brain Metastases: Secondary Analysis of the JROSG 99-1 Randomized Clinical Trial.
Aoyama H; Tago M; Shirato H;
JAMA Oncol; 2015 Jul; 1(4):457-64. PubMed ID: 26181254
[TBL] [Abstract][Full Text] [Related]
10. A New Diagnosis-Specific Survival Score for Patients to be Irradiated for Brain Metastases from Non-small Cell Lung Cancer.
Rades D; Hansen HC; Schild SE; Janssen S
Lung; 2019 Jun; 197(3):321-326. PubMed ID: 30927058
[TBL] [Abstract][Full Text] [Related]
11. Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.
Yang JJ; Zhou C; Huang Y; Feng J; Lu S; Song Y; Huang C; Wu G; Zhang L; Cheng Y; Hu C; Chen G; Zhang L; Liu X; Yan HH; Tan FL; Zhong W; Wu YL
Lancet Respir Med; 2017 Sep; 5(9):707-716. PubMed ID: 28734822
[TBL] [Abstract][Full Text] [Related]
12. A phase III trial of topotecan and whole brain radiation therapy for patients with CNS-metastases due to lung cancer.
Neuhaus T; Ko Y; Muller RP; Grabenbauer GG; Hedde JP; Schueller H; Kocher M; Stier S; Fietkau R
Br J Cancer; 2009 Jan; 100(2):291-7. PubMed ID: 19127261
[TBL] [Abstract][Full Text] [Related]
13. Hypofractionated stereotactic radiotherapy with or without whole-brain radiotherapy for patients with newly diagnosed brain metastases from non-small cell lung cancer.
Ma LH; Li G; Zhang HW; Wang ZY; Dang J; Zhang S; Yao L; Zhang XM
J Neurosurg; 2012 Dec; 117 Suppl():49-56. PubMed ID: 23205789
[TBL] [Abstract][Full Text] [Related]
14. A review of whole brain radiotherapy outcomes in a high epidermal growth factor receptor mutation rate population: Does QUARTZ apply in Asia?
Ng IW; Tey JCS; Chia DWT; Yee CM; Cheo TST
Asia Pac J Clin Oncol; 2019 Dec; 15(6):353-357. PubMed ID: 31267659
[TBL] [Abstract][Full Text] [Related]
15. Whole brain radiotherapy after stereotactic radiosurgery or surgical resection among patients with one to three brain metastases and favorable prognoses: a secondary analysis of EORTC 22952-26001.
Churilla TM; Handorf E; Collette S; Collette L; Dong Y; Aizer AA; Kocher M; Soffietti R; Alexander BM; Weiss SE
Ann Oncol; 2017 Oct; 28(10):2588-2594. PubMed ID: 28961826
[TBL] [Abstract][Full Text] [Related]
16. A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320.
Sperduto PW; Wang M; Robins HI; Schell MC; Werner-Wasik M; Komaki R; Souhami L; Buyyounouski MK; Khuntia D; Demas W; Shah SA; Nedzi LA; Perry G; Suh JH; Mehta MP
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1312-8. PubMed ID: 23391814
[TBL] [Abstract][Full Text] [Related]
17. Whole-brain radiation therapy plus concomitant temozolomide for the treatment of brain metastases from non-small-cell lung cancer: a randomized, open-label phase II study.
Chua D; Krzakowski M; Chouaid C; Pallotta MG; Martinez JI; Gottfried M; Curran W; Throuvalas N
Clin Lung Cancer; 2010 May; 11(3):176-81. PubMed ID: 20439193
[TBL] [Abstract][Full Text] [Related]
18. Motexafin gadolinium combined with prompt whole brain radiotherapy prolongs time to neurologic progression in non-small-cell lung cancer patients with brain metastases: results of a phase III trial.
Mehta MP; Shapiro WR; Phan SC; Gervais R; Carrie C; Chabot P; Patchell RA; Glantz MJ; Recht L; Langer C; Sur RK; Roa WH; Mahe MA; Fortin A; Nieder C; Meyers CA; Smith JA; Miller RA; Renschler MF
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1069-76. PubMed ID: 18977094
[TBL] [Abstract][Full Text] [Related]
19. Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases.
Lee SM; Lewanski CR; Counsell N; Ottensmeier C; Bates A; Patel N; Wadsworth C; Ngai Y; Hackshaw A; Faivre-Finn C
J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 25031274
[TBL] [Abstract][Full Text] [Related]
20. Survival after whole brain radiotherapy for brain metastases from lung cancer and breast cancer is poor in 6325 Dutch patients treated between 2000 and 2014.
Jeene PM; de Vries KC; van Nes JGH; Kwakman JJM; Wester G; Rozema T; Braam PM; Zindler JD; Koper P; Nuyttens JJ; Vos-Westerman HA; Schmeets I; Niël CGHJ; Hutschemaekers S; van der Linden YM; Verhoeff JJC; Stalpers LJA
Acta Oncol; 2018 May; 57(5):637-643. PubMed ID: 29276848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
